Author of

• 10720

  +

  P1.09 - Poster Session 1 - Combined Modality (ID 212)

  • Event: WCLC 2013
  • Type: Poster Session
  • Track: Combined Modality
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/28/2013, 09:30 - 16:30, Exhibit Hall, Ground Level

  • 10739

    +

    P1.09-019 - Survival analysis and EGFR gene mutation study for locally advanced non-small cell lung cancer in patients treated with curative intention. (ID 2966)

    09:30 - 09:30  |  Author(s): J. Molero
    • Abstract

    Background
    On 2005 began the EGFR gene mutations determination in our Centre. We want to know the survival of patients with locally advanced non-small cell lung cancer treated with radical intention and to determine if there is a dependency for the EGFR gene mutation status.

    Methods
    We have treated 399 patients with locally advanced non-small cell lung cancer from 2005 until now. Mean age is 63,38 years (range 26-86). By gender, 346 patients were males (87%) and 53 were females (13%). All the patients were treated in our Department of Radiation Oncology. Squamous cell carcinoma was found in 188 patients (47%), adenocarcinoma in 169 patients (42%) and 42 patients (11%) had large cell or undifferentiated carcinomas. The majority of cases of radical treatment received concomitant radiotherapy and chemotherapy. Radiotherapy in stage IIIA (222 patients) was adjuvant to surgery in 53 cases, preoperatory in 1 patient and was administered with curative intent, with or without chemotherapy, to the rest of patients of stage IIIA. All the patients in stage IIIB disease (177 patients) received curative radiotherapy with or without chemotherapy. Conventional daily 3-D radiotherapy at standard fractionation was used and median dose of radiotherapy was 50 Gy in adjuvancy and 66 Gy (range 2-70) in curative intention. EGFR gene mutation determination was performed in 99 patients.

    Results
    Five-year overall survival for all patients is 22.8%, with a median survival of 22 months. By stage, 5-year overall survival is 29% for stage IIIA (median survival of 26 months) and 16.2% for stage IIIB (median survival of 20 months). Five-year overall survival for non-surgical stage IIIA disease is 17.1%, being the median survival 18 months and showing no difference with patients with stage IIIB disease. For the 99 patients analyzed for the EGFR gene status, the mutation was present in 9 patients while 90 patients were wild type. The overall 5-year survival for the patients whom the EGFR mutation was determined is 24% (median of 30 months) and there is no difference with the survival found for all patients. The EGFR gene status mutation does not imply a difference in survival.

    Conclusion
    The survival for stage III non-small cell lung cancer remains about 15% at 5 years and there is no difference for inoperable stages IIIA and IIIB. Median survival has achieved 20 months, which is better than the previous observed in the last decade of twentieth century. Given the small size of the sample with EGFR gene mutation (9 cases) we cannot conclude whether or not this factor has a prognostic value.